{"id":"NCT01817075","sponsor":"Children's Oncology Group","briefTitle":"Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant","officialTitle":"Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11-04","primaryCompletion":"2019-03-31","completion":"2020-03-31","firstPosted":"2013-03-22","resultsPosted":"2020-04-08","lastUpdate":"2021-06-22"},"enrollment":177,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Bacterial Infection","Benign Neoplasm","Malignant Neoplasm","Methicillin-Resistant Staphylococcus Aureus Infection","Myeloid Neoplasm","Recurrent Childhood Acute Lymphoblastic Leukemia","Recurrent Childhood Acute Myeloid Leukemia"],"interventions":[{"type":"PROCEDURE","name":"Chlorhexidine Gluconate Skin Cleanser","otherNames":["Skin Cleanser with Chlorhexidine Gluconate"]},{"type":"OTHER","name":"Laboratory Biomarker Analysis","otherNames":[]},{"type":"PROCEDURE","name":"Mild Soap Skin Cleanser","otherNames":["Skin Cleanser with Mild Soap"]},{"type":"OTHER","name":"Questionnaire Administration","otherNames":[]}],"arms":[{"label":"Arm I (CHG cleansing wipe)","type":"EXPERIMENTAL"},{"label":"Arm II (control)","type":"ACTIVE_COMPARATOR"}],"summary":"This randomized phase III trial studies chlorhexidine gluconate cleansing to see how well it works compared to control cleansing in preventing central line associated bloodstream infection and acquisition of multi-drug resistant organisms in younger patients with cancer or undergoing donor stem cell transplant. Chlorhexidine gluconate may help reduce bloodstream infections and bacterial infections associated with the central line.","primaryOutcome":{"measure":"Central Line-associated Bloodstream Infections (CLABSI) Events During the At-risk Days","timeFrame":"Up to 90 days post enrollment date","effectByArm":[{"arm":"Arm I (CHG Cleansing Wipe)","deltaMin":5.44,"sd":null},{"arm":"Arm II (Control)","deltaMin":3.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":59,"countries":["United States","Canada","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":["https://nctn-data-archive.nci.nih.gov/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":88},"commonTop":["Rash maculo-papular","Skin and subcutaneous tissue disorders - Other, specify","Urticaria","Hypercalcemia","Mucositis oral"]}}